TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03140085
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application
Study: NCT01575288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100g maltose 1/day
Study: NCT01418352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole matching-placebo once-weekly for 8 weeks.
Study: NCT02964884
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
Study: NCT02964884
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those in the placebo group will receive a tablet daily
Study: NCT03236493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as tablet
Study: NCT03676764
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
Study: NCT03676764
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
Study: NCT00819546
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
Study: NCT00819546
Drug: PKC412
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
Study: NCT04495894
Drug: Preoperative Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
Study: NCT00947245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, Single Dose, One day
Study: NCT00947245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, Every 12 hours, 14 days
Study: NCT00947245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, Once Daily, 14 days
Study: NCT00947245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, Every 12 hours or once daily, 14 days
Study: NCT03603431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo
Study: NCT03603431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Placebo
Study: NCT00962182
Drug: STAN1
Normalized name: Stan Gard 0.4 % Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 capsules/day at meals
Study: NCT00962182
Drug: Placebo enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 capsules/day at meals
Study: NCT00962182
Drug: STAN1+gluten
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 capsules/day at meals plus 500 mg gluten b.i.d
Study: NCT00527397
Drug: CP-464,005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
Study: NCT00527397
Drug: CP-464,005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
Study: NCT00367770
Drug: Tracleer®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to 125 mg b.i.d. of Tracleer.
Study: NCT01108978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study: NCT01108978
Drug: Dehypotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study: NCT02480712
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT00862888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral solution
Study: NCT00862888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for tablet
Study: NCT04619069
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Hormone Therapy per physician discretion (Min. 8 months)
Study: NCT04336488
Drug: Kenacort A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of both drugs 3 times daily for 3 weeks as an active control
Study: NCT00479401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03296553
Drug: Antiretroviral Combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard antiretroviral treatment as recommended
Study: NCT02023866
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine Bitartrate Delayed-release capsules
Study: NCT00298025
Drug: Recombinant Human Choriogonadotropin (r-hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
Study: NCT02125643
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00095680
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 30-mg capsules three times daily
Study: NCT05535595
Drug: genotyping and selection of renin-angiotensin system blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping
Study: NCT00558519
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00558519
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00558519
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00558519
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01755611
Drug: Minocycline 100mg
Normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product
Study: NCT01755611
Drug: Minocycline 100mg
Normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference product
Study: NCT00567528
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
Study: NCT00567528
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
Study: NCT00478101
Drug: oxycodone fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01125943
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial infusion
Study: NCT01013649
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01013649
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given combination chemotherapy
Study: NCT01013649
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00332839
Drug: Enteric Coated - Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose was ≥ 720 mg/day.
Study: NCT00046371
Drug: THERATOPE® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02455141
Drug: Epirubicin plus Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
Study: NCT02455141
Drug: Taxanes
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
Study: NCT00332839
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids were given according to local standard and/or the Investigators' discretion.
Study: NCT00303381
Drug: Interferon-beta-1a, 44 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
Study: NCT00303381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
Study: NCT00303381
Drug: Interferon-beta-1a, 66 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
Study: NCT03447470
Drug: RXC004
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
Study: NCT03363425
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04246255
Drug: Xylocaine 10% Oral
Normalized name: Xylocaine 10% Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Study: NCT04246255
Drug: Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Study: NCT01606215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00558571
Drug: placebo to BI 10773
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00817466
Drug: Racemic adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: For inhalation.~Dosing (as in previous study):~1) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number.
Study: NCT00817466
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml NaCl 9mg/ml.
Study: NCT02514954
Drug: Biochaperone® Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of an individualized dose
Study: NCT02514954
Drug: Humalog® Mix25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of an individualized dose
Study: NCT01154127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Study: NCT04464707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02581839
Drug: Pre-Medication: Zofran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofran at 8mg orally. Given at the discretion of the treating physician
Study: NCT02581839
Drug: Pre-Medication: Decadron
Approvals — FDA: no, EMA: no, PMDA: no
Description: decadron at 8mg orally. Given at the discretion of the treating physician
Study: NCT04352777
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole, anastrozole as prescribed per standard of care
Study: NCT03448081
Drug: SNA-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNA-120 (0.5%) active ointment
Study: NCT03448081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ointment
Study: NCT00796354
Drug: MOVICOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
Study: NCT04592549
Drug: ADM03820
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
Study: NCT03804944
Drug: Pembrolizumab (200mg IV for 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT02536833
Drug: SM04690
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02536833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04285567
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
Study: NCT00695201
Drug: Floxuridine, Oxaliplatin, CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
Study: NCT00695201
Drug: Floxuridine, Oxaliplatin, CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
Study: NCT00938964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine versus placebo infusion for 48 hours
Study: NCT03455764
Drug: MCS110
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
Study: NCT00655135
Drug: LDP-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
Study: NCT00655135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
Study: NCT01211587
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
Study: NCT00730262
Drug: TLN-4601
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
Study: NCT03524118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
Study: NCT00453388
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04627064
Drug: MK-6482
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken orally
Study: NCT01309828
Drug: Azilsartan medoxomil and chlorthalidone
Normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets.
Study: NCT04452929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of saline placebo.
Study: NCT00811070
Drug: SKI-606 (Bosutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing.
Study: NCT01522586
Drug: DWP09031
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Study: NCT01522586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Study: NCT01845701
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
Study: NCT02582801
Drug: 18F-Alfatide Ⅱ PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Study: NCT04582409
Drug: HSY244
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSY244 concentrate solution for injection via intravenous infusion
Study: NCT01771185
Drug: Best medical treatment (Metformin ; gliclazide)
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2 g/day; gliclazide 30 mg
Study: NCT04219280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid solution to mimic the color and taste of Quillivant XR.
Study: NCT00238511
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02407028
Drug: Normobaric Hyperoxia (NBH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
Study: NCT01759485
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01511185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered subcutaneously in random order
Study: NCT02577783
Drug: PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
Study: NCT02577783
Drug: PAD regimen: bortizomib, dexamethasone and doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
Study: NCT01163032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, PO daily for 6 months
Study: NCT00621894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00198978
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00198978
Drug: Dexamethasone / Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00392821
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001
Study: NCT01753739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
Study: NCT00371501
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/day
Study: NCT00371501
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet/day
Study: NCT00371501
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02021656
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily without regard to food
Study: NCT01687374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection daily for 8 weeks.
Study: NCT03972306
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
Study: NCT00198978
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no